8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin

Naos Suzuki, Daisuke Aoki, K. Orikawa, A. Suzuki, N. Susumu, Y. Tamada, M. Sakayori, K. Tsukazaki, M. Mukai, H. Kikuchi, I. Ishida, S. Nozawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The incidence of choriocarcinoma has decreased over time and therapeutic results have improved about 90% complete remission in patients without extensive metastasis. However, some choriocarcinomas metastasize to other organs and show resistance to chemotherapy, having a poor prognosis despite multidisciplinary treatment. Better methods of early diagnosis for recurrence or micrometastasis, and treatment against cases with intractable gestational trophoblastic neoplasia (GTN) are needed to improve the prognosis. Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of two dissimilar subunits and a tumor marker to make a diagnosis and monitor therapeutic effect in GTN. Even when hCG levels in the serum become too low to measure with the hCG β-CTP system which is the most sensitive assay, there are estimated to be approximately 10,000 trophoblastic cells in the body. Residual trophoblast cells may cause symptoms such as bleeding or undergo malignant transformation to choriocarcinoma. Since most monoclonal antibodies developed so far are murine, administration creates human anti-mouse antibodies, resulting in clinical failure. More recent mouse/human chimeric antibodies or humanized antibodies still possess substantial immunogenicity that makes repeated administration difficult. In the present study, KM mice that can produce completely human monoclonal antibodies were used to prepare hCG-specific human monoclonal antibody. This yielded 8-1A, a human monoclonal antibody capable of reacting with intact hCG. In the future, new diagnostic techniques and treatments for chorionic diseases may be developed using this kind of human monoclonal antibody.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalPlacenta
Volume27
Issue number2-3
DOIs
Publication statusPublished - 2006 Feb

Fingerprint

Chorionic Gonadotropin
Choriocarcinoma
Monoclonal Antibodies
Gestational Trophoblastic Disease
Antibodies, Monoclonal, Humanized
Cytidine Triphosphate
Neoplasm Micrometastasis
Trophoblasts
Therapeutic Uses
Therapeutics
Tumor Biomarkers
Early Diagnosis
Anti-Idiotypic Antibodies
Glycoproteins
human 8-1A monoclonal antibody
Hormones
Hemorrhage
Neoplasm Metastasis
Recurrence
Drug Therapy

Keywords

  • hCG
  • Human monoclonal antibody
  • KM mice

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Suzuki, N., Aoki, D., Orikawa, K., Suzuki, A., Susumu, N., Tamada, Y., ... Nozawa, S. (2006). 8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin. Placenta, 27(2-3), 333-339. https://doi.org/10.1016/j.placenta.2005.02.005

8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin. / Suzuki, Naos; Aoki, Daisuke; Orikawa, K.; Suzuki, A.; Susumu, N.; Tamada, Y.; Sakayori, M.; Tsukazaki, K.; Mukai, M.; Kikuchi, H.; Ishida, I.; Nozawa, S.

In: Placenta, Vol. 27, No. 2-3, 02.2006, p. 333-339.

Research output: Contribution to journalArticle

Suzuki, N, Aoki, D, Orikawa, K, Suzuki, A, Susumu, N, Tamada, Y, Sakayori, M, Tsukazaki, K, Mukai, M, Kikuchi, H, Ishida, I & Nozawa, S 2006, '8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin', Placenta, vol. 27, no. 2-3, pp. 333-339. https://doi.org/10.1016/j.placenta.2005.02.005
Suzuki, Naos ; Aoki, Daisuke ; Orikawa, K. ; Suzuki, A. ; Susumu, N. ; Tamada, Y. ; Sakayori, M. ; Tsukazaki, K. ; Mukai, M. ; Kikuchi, H. ; Ishida, I. ; Nozawa, S. / 8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin. In: Placenta. 2006 ; Vol. 27, No. 2-3. pp. 333-339.
@article{d70cf54802c844ed82043ab457a52d90,
title = "8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin",
abstract = "The incidence of choriocarcinoma has decreased over time and therapeutic results have improved about 90{\%} complete remission in patients without extensive metastasis. However, some choriocarcinomas metastasize to other organs and show resistance to chemotherapy, having a poor prognosis despite multidisciplinary treatment. Better methods of early diagnosis for recurrence or micrometastasis, and treatment against cases with intractable gestational trophoblastic neoplasia (GTN) are needed to improve the prognosis. Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of two dissimilar subunits and a tumor marker to make a diagnosis and monitor therapeutic effect in GTN. Even when hCG levels in the serum become too low to measure with the hCG β-CTP system which is the most sensitive assay, there are estimated to be approximately 10,000 trophoblastic cells in the body. Residual trophoblast cells may cause symptoms such as bleeding or undergo malignant transformation to choriocarcinoma. Since most monoclonal antibodies developed so far are murine, administration creates human anti-mouse antibodies, resulting in clinical failure. More recent mouse/human chimeric antibodies or humanized antibodies still possess substantial immunogenicity that makes repeated administration difficult. In the present study, KM mice that can produce completely human monoclonal antibodies were used to prepare hCG-specific human monoclonal antibody. This yielded 8-1A, a human monoclonal antibody capable of reacting with intact hCG. In the future, new diagnostic techniques and treatments for chorionic diseases may be developed using this kind of human monoclonal antibody.",
keywords = "hCG, Human monoclonal antibody, KM mice",
author = "Naos Suzuki and Daisuke Aoki and K. Orikawa and A. Suzuki and N. Susumu and Y. Tamada and M. Sakayori and K. Tsukazaki and M. Mukai and H. Kikuchi and I. Ishida and S. Nozawa",
year = "2006",
month = "2",
doi = "10.1016/j.placenta.2005.02.005",
language = "English",
volume = "27",
pages = "333--339",
journal = "Placenta",
issn = "0143-4004",
publisher = "W.B. Saunders Ltd",
number = "2-3",

}

TY - JOUR

T1 - 8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin

AU - Suzuki, Naos

AU - Aoki, Daisuke

AU - Orikawa, K.

AU - Suzuki, A.

AU - Susumu, N.

AU - Tamada, Y.

AU - Sakayori, M.

AU - Tsukazaki, K.

AU - Mukai, M.

AU - Kikuchi, H.

AU - Ishida, I.

AU - Nozawa, S.

PY - 2006/2

Y1 - 2006/2

N2 - The incidence of choriocarcinoma has decreased over time and therapeutic results have improved about 90% complete remission in patients without extensive metastasis. However, some choriocarcinomas metastasize to other organs and show resistance to chemotherapy, having a poor prognosis despite multidisciplinary treatment. Better methods of early diagnosis for recurrence or micrometastasis, and treatment against cases with intractable gestational trophoblastic neoplasia (GTN) are needed to improve the prognosis. Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of two dissimilar subunits and a tumor marker to make a diagnosis and monitor therapeutic effect in GTN. Even when hCG levels in the serum become too low to measure with the hCG β-CTP system which is the most sensitive assay, there are estimated to be approximately 10,000 trophoblastic cells in the body. Residual trophoblast cells may cause symptoms such as bleeding or undergo malignant transformation to choriocarcinoma. Since most monoclonal antibodies developed so far are murine, administration creates human anti-mouse antibodies, resulting in clinical failure. More recent mouse/human chimeric antibodies or humanized antibodies still possess substantial immunogenicity that makes repeated administration difficult. In the present study, KM mice that can produce completely human monoclonal antibodies were used to prepare hCG-specific human monoclonal antibody. This yielded 8-1A, a human monoclonal antibody capable of reacting with intact hCG. In the future, new diagnostic techniques and treatments for chorionic diseases may be developed using this kind of human monoclonal antibody.

AB - The incidence of choriocarcinoma has decreased over time and therapeutic results have improved about 90% complete remission in patients without extensive metastasis. However, some choriocarcinomas metastasize to other organs and show resistance to chemotherapy, having a poor prognosis despite multidisciplinary treatment. Better methods of early diagnosis for recurrence or micrometastasis, and treatment against cases with intractable gestational trophoblastic neoplasia (GTN) are needed to improve the prognosis. Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of two dissimilar subunits and a tumor marker to make a diagnosis and monitor therapeutic effect in GTN. Even when hCG levels in the serum become too low to measure with the hCG β-CTP system which is the most sensitive assay, there are estimated to be approximately 10,000 trophoblastic cells in the body. Residual trophoblast cells may cause symptoms such as bleeding or undergo malignant transformation to choriocarcinoma. Since most monoclonal antibodies developed so far are murine, administration creates human anti-mouse antibodies, resulting in clinical failure. More recent mouse/human chimeric antibodies or humanized antibodies still possess substantial immunogenicity that makes repeated administration difficult. In the present study, KM mice that can produce completely human monoclonal antibodies were used to prepare hCG-specific human monoclonal antibody. This yielded 8-1A, a human monoclonal antibody capable of reacting with intact hCG. In the future, new diagnostic techniques and treatments for chorionic diseases may be developed using this kind of human monoclonal antibody.

KW - hCG

KW - Human monoclonal antibody

KW - KM mice

UR - http://www.scopus.com/inward/record.url?scp=28844431574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844431574&partnerID=8YFLogxK

U2 - 10.1016/j.placenta.2005.02.005

DO - 10.1016/j.placenta.2005.02.005

M3 - Article

VL - 27

SP - 333

EP - 339

JO - Placenta

JF - Placenta

SN - 0143-4004

IS - 2-3

ER -